Objective: To investigate the association of downregulated CDH13 expression with invasiveness of bladder transitional cell carcinoma (TCC). Materials and Methods: CDH13 and matrix metalloproteinase-2 (MMP2) expression was detected in 23 normal bladder epithelial tissues and 71 bladder TCC tissues. RNA interference was used to inhibit CDH13 expression in bladder TCC 5637 cells and then analyzed its effects on migration, invasion, adhesion, and proliferation of 5637 cells, as well as MMP2 expression in 5637 cells. Results: The CDH13 expression in bladder TCC tissues was significantly lower than that in normal bladder epithelial tissues. Moreover, the expression of CDH13 from the muscle-invasive group was significantly lower than that from the non-muscle-invasive group. In addition, the MMP2 expression was increased in bladder TCC, especially in muscle-invasive tumors. After the transfection of CDH13 siRNA into 5637 cells, CDH13 expression was significantly decreased, and the migration, invasion, adhesion of 5637 cells, as well as MMP2 expression in 5637 cells was significantly promoted compared with blank and negative controls. Conclusions: Downregulated expression of CDH13 is associated with increased invasion of bladder TCC, and may be due to the enhancement of cell-extracellular matrix adhesion and increased MMP2 expression.

Keywords:
CDH13, Bladder cancer, Invasion
1.
Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-293.
2.
Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-442.
3.
Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010;60:244-272.
4.
Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176:2414-2422.
5.
Morgan TM, Clark PE: Bladder cancer. Curr Opin Oncol 2010;22:242-249.
6.
Andreeva AV, Kutuzov MA: Cadherin 13 in cancer. Genes Chromosomes Cancer 2010;49:775-790.
7.
Philippova M, Joshi MB, Kyriakakis E, Pfaff D, Erne P, Resink TJ: A guide and guard: the many faces of T-cadherin. Cell Signal 2009;21:1035-1044.
8.
Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J: A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 2007;13:7296-7304.
9.
Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-8663.
10.
Lin YL, Liu XQ, Li WP, Sun G, Zhang CT: Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol 2012;44:111-117.
11.
Mao Q, Li Y, Zheng X, Yang K, Shen H, Qin J, Bai Y, Kong D, Jia X, Xie L: Up-regulation of E-cadherin by small activating RNA inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun 2008;375:566-570.
12.
Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA: Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003;282:48-57.
13.
Adachi Y, Takeuchi T, Nagayama T, Furihata M: T-cadherin modulates tumor-associated molecules in gallbladder cancer cells. Cancer Invest 2010;28:120-126.
14.
Alameh M, Jean M, Dejesus D, Buschmann MD, Merzouki A: Chitosanase-based method for RNA isolation from cells transfected with chitosan/siRNA nanocomplexes for -real-time RT-PCR in gene silencing. Int J Nanomed 2010;5:473-481.
15.
Shen A, Zhang Y, Yang H, Xu R, Huang G: Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J Surg Oncol 2012;105:830-834.
16.
Wang B, Xu YF, He BS, Pan YQ, Zhang LR, Zhu C, Qu LL, Wang SK: RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res 2010;29:61.
17.
Chen RX, Xia YH, Xue TC, Ye SL: Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res 2010;29:172.
18.
Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG: The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009;9:280.
19.
Lin Y, Sun G, Liu X, Chen Y, Zhang C: Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int 2011;86:340-345.
20.
Martin TA, Mason MD, Jiang WG: Tight junctions in cancer metastasis. Front Biosci 2011;16:898-936.
21.
Moh MC, Shen S: The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adh Migr 2009;3:334-336.
22.
Riou P, Saffroy R, Chenailler C, Franc B, Gentile C, Rubinstein E, Resink T, Debuire B, Piatier-Tonneau D, Lemoine A: Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma. FASEB J 2006;20:2291-2301.
23.
Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N: T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol 2005;124:833-838.
24.
Huang ZY, Wu Y, Hedrick N, Gutmann DH: T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol 2003;23:566-578.
25.
Gritsenko PG, Ilina O, Friedl P: Interstitial guidance of cancer invasion. J Pathol 2012;226:185-199.
26.
Mohammad MA, Ismael NR, Shaarawy SM, El-Merzabani MM: Prognostic value of membrane type 1 and 2 matrix metalloproteinase expression and gelatinase A activity in bladder cancer. Int J Biol Markers 2010; 25:69-74.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.